LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

2.17 -9.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.14

Max

2.42

Põhinäitajad
By Trading Economics
Sissetulek	-124K -32M
Müük	-372K 1.4M
Aktsiakasum	-0.27
Kasumimarginaal	-2,364.792
Töötajad	161
EBITDA	-13M -42M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+109.21% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	18. mai 2026

Turustatistika
By TradingEconomics
Turukapital	35M 209M
Eelmine avamishind	11.38
Eelmine sulgemishind	2.17

Uudiste sentiment

By Acuity

41%

59%

146 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11. mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11. mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11. mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11. mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11. mai 2026, 22:32 UTC

Tulu

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11. mai 2026, 22:02 UTC

Market Talk

Uudisväärsed sündmused

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11. mai 2026, 21:49 UTC

Tulu

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11. mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11. mai 2026, 21:32 UTC

Omandamised, ülevõtmised, äriostud

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11. mai 2026, 21:31 UTC

Omandamised, ülevõtmised, äriostud

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11. mai 2026, 21:23 UTC

Omandamised, ülevõtmised, äriostud

CSG Systems Sale to NEC Gets CFIUS Clearance

11. mai 2026, 21:12 UTC

Tulu

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11. mai 2026, 21:12 UTC

Tulu

Ovintiv 1Q Loss/Shr $2.35 >OVV

11. mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11. mai 2026, 20:44 UTC

Tulu

Steris: Board Approves New $1B Shr Repurchase Program >STE

11. mai 2026, 20:43 UTC

Tulu

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11. mai 2026, 20:32 UTC

Tulu

CleanSpark 2Q Rev $136.4M >CLSK

11. mai 2026, 20:30 UTC

Tulu

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Cont Ops EPS $2.24 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Rev $1.6B >STE

11. mai 2026, 20:30 UTC

Tulu

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11. mai 2026, 20:30 UTC

Tulu

Steris 4Q Adj EPS $2.83 >STE

11. mai 2026, 20:22 UTC

Kuumad aktsiad

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11. mai 2026, 19:37 UTC

Tulu

More Bad News at KKR's Private Credit Fund -- Barrons.com

11. mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

109.21% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 109.21%

Kõrge 7 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

146 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.